Abstract
The release of a gross cystic disease fluid protein (GCDFP 15) by tumour explants grown in tissue culture was used to measure apocrine differentiation in 117 women with breast carcinoma. GCDFP 15 was detected by radioimmunoassay in the media from 90% of tumours (range 2–2100 ng/ml, mean 41). Tumour secretion of GCDFP 15 was higher in oestrogen receptor rich (over 20 fmol/mg) tumour ( P <0.05) but did not correlate with any other prognostic factors or with survival. Response to hormonal therapy was assessable by UICC criteria in 33 women (6 partial responses, 8 stable disease, 19 progression). Responders had significantly higher tumour oestrogen receptor levels ( P < 0.005) but a lower GCDFP 15 secretion than non-responders ( P < 0.02). Apocrine differentiation in breast cancer may be a marker for oestrogen receptor positive tumours that do not respond to hormonal therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
